Hoth Therapeutics (HOTH) Competitors $0.84 -0.01 (-1.28%) Closing price 04:00 PM EasternExtended Trading$0.84 +0.01 (+1.20%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOTH vs. ATNM, STTK, ICCC, VRCA, OKYO, ONCY, CUE, MURA, NBRV, and QNCXShould you be buying Hoth Therapeutics stock or one of its competitors? The main competitors of Hoth Therapeutics include Actinium Pharmaceuticals (ATNM), Shattuck Labs (STTK), ImmuCell (ICCC), Verrica Pharmaceuticals (VRCA), OKYO Pharma (OKYO), Oncolytics Biotech (ONCY), Cue Biopharma (CUE), Mural Oncology (MURA), Nabriva Therapeutics (NBRV), and Quince Therapeutics (QNCX). These companies are all part of the "pharmaceutical products" industry. Hoth Therapeutics vs. Actinium Pharmaceuticals Shattuck Labs ImmuCell Verrica Pharmaceuticals OKYO Pharma Oncolytics Biotech Cue Biopharma Mural Oncology Nabriva Therapeutics Quince Therapeutics Actinium Pharmaceuticals (NYSE:ATNM) and Hoth Therapeutics (NASDAQ:HOTH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment. Does the MarketBeat Community favor ATNM or HOTH? Hoth Therapeutics received 67 more outperform votes than Actinium Pharmaceuticals when rated by MarketBeat users. Likewise, 67.24% of users gave Hoth Therapeutics an outperform vote while only 47.83% of users gave Actinium Pharmaceuticals an outperform vote. CompanyUnderperformOutperformActinium PharmaceuticalsOutperform Votes1147.83% Underperform Votes1252.17% Hoth TherapeuticsOutperform Votes7867.24% Underperform Votes3832.76% Which has better earnings and valuation, ATNM or HOTH? Hoth Therapeutics has lower revenue, but higher earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Hoth Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActinium Pharmaceuticals$81K704.80-$48.82M-$1.39-1.32Hoth TherapeuticsN/AN/A-$7.84M-$1.14-0.74 Which has more risk and volatility, ATNM or HOTH? Actinium Pharmaceuticals has a beta of -0.24, meaning that its stock price is 124% less volatile than the S&P 500. Comparatively, Hoth Therapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Does the media favor ATNM or HOTH? In the previous week, Actinium Pharmaceuticals had 25 more articles in the media than Hoth Therapeutics. MarketBeat recorded 25 mentions for Actinium Pharmaceuticals and 0 mentions for Hoth Therapeutics. Hoth Therapeutics' average media sentiment score of 0.89 beat Actinium Pharmaceuticals' score of -0.05 indicating that Hoth Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Actinium Pharmaceuticals Neutral Hoth Therapeutics Positive Do institutionals & insiders believe in ATNM or HOTH? 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Hoth Therapeutics shares are owned by institutional investors. 6.0% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 10.6% of Hoth Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is ATNM or HOTH more profitable? Hoth Therapeutics' return on equity of -89.68% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Actinium PharmaceuticalsN/A -100.85% -47.89% Hoth Therapeutics N/A -89.68%-82.61% Do analysts recommend ATNM or HOTH? Actinium Pharmaceuticals currently has a consensus target price of $4.00, indicating a potential upside of 118.58%. Hoth Therapeutics has a consensus target price of $4.00, indicating a potential upside of 372.93%. Given Hoth Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Hoth Therapeutics is more favorable than Actinium Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actinium Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Hoth Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 SummaryHoth Therapeutics beats Actinium Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get Hoth Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOTH vs. The Competition Export to ExcelMetricHoth TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.17M$6.54B$5.43B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-0.649.1426.7920.05Price / SalesN/A255.59395.67116.44Price / CashN/A65.8538.2534.62Price / Book0.426.546.864.61Net Income-$7.84M$143.51M$3.22B$248.19M7 Day Performance-2.78%5.60%6.80%2.97%1 Month Performance9.63%10.06%13.69%16.58%1 Year Performance-28.61%-0.86%18.25%8.16% Hoth Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOTHHoth Therapeutics3.3149 of 5 stars$0.84-1.3%$4.00+379.0%-29.5%$11.03MN/A-0.634ATNMActinium Pharmaceuticals1.2133 of 5 stars$1.55+4.7%$4.00+158.1%N/A$48.35M$81,000.00-1.1230Trending NewsSTTKShattuck Labs2.5855 of 5 stars$0.99+4.4%$7.50+657.6%-86.2%$47.42M$4.61M-0.65100Gap UpICCCImmuCell0.169 of 5 stars$5.24+3.4%N/A+16.9%$47.13M$26.49M-10.4870Earnings ReportVRCAVerrica Pharmaceuticals4.2265 of 5 stars$0.51+15.1%$9.50+1,776.4%-92.6%$46.81M$7.57M-0.2840Analyst RevisionOKYOOKYO Pharma1.7534 of 5 stars$1.38-4.8%$7.00+407.2%+24.2%$46.69MN/A0.007ONCYOncolytics Biotech1.7396 of 5 stars$0.54+4.0%$4.33+702.5%-61.6%$46.67MN/A-2.0030Earnings ReportAnalyst ForecastGap DownCUECue Biopharma3.8841 of 5 stars$0.75-3.7%$3.00+299.5%-64.2%$46.43M$9.29M-0.8360MURAMural Oncology2.3312 of 5 stars$2.64+0.4%$13.00+392.4%-21.0%$45.59MN/A-0.29119Positive NewsEarnings ReportGap DownNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070QNCXQuince Therapeutics2.908 of 5 stars$1.03+1.0%$8.00+676.7%+13.4%$45.45MN/A-0.8360 Related Companies and Tools Related Companies Actinium Pharmaceuticals Alternatives Shattuck Labs Alternatives ImmuCell Alternatives Verrica Pharmaceuticals Alternatives OKYO Pharma Alternatives Oncolytics Biotech Alternatives Cue Biopharma Alternatives Mural Oncology Alternatives Nabriva Therapeutics Alternatives Quince Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOTH) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hoth Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hoth Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HOTH Stock Free HOTH Stock Alerts